Immucell (ICCC) Other Non-Current Liabilities (2017 - 2023)

Immucell's (ICCC) quarterly Other Non-Current Liabilities came in at $9.3 million in Q2 2023, down 3.33% on a QoQ basis from $9.6 million in Q1 2023.

Immucell (ICCC) Other Non-Current Liabilities (2017 - 2023) Analysis & Trends

Immucell (ICCC) has 3 years of Other Non-Current Liabilities data on file, last reported at $9.3 million in Q2 2023.

Quarterly Other Non-Current Liabilities changed N/A year-over-year to $9.3 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $9.3 million (changed N/A YoY) and the FY2019 annual result came in at $58526.0, changed N/A from the prior year.
Other Non-Current Liabilities retreated to $9.3 million in Q2 2023, from $9.6 million in the prior quarter.
In the past five years, Other Non-Current Liabilities ranged from a high of $9.6 million in Q1 2023 to a low of $57216.0 in Q2 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Immucell	91.19 Mn	82.33 Mn	2.44 Mn

Download Data